A class action lawsuit has been initiated against REGENXBIO Inc., alleging the biopharmaceutical company made materially false and misleading statements regarding its RGX-111 gene therapy development program and associated clinical trial results. The litigation, brought by investors through legal counsel at Bronstein, Gewirtz & Grossman LLC, targets the period between February 9, 2022 and January 27, 2026, during which shareholders claim to have purchased company securities based on inaccurate disclosures.
The lawsuit represents a collective action by affected shareholders seeking damages for losses attributed to the company's alleged misrepresentations. Investors who purchased REGENXBIO securities during the specified timeframe may qualify as class members in the proceeding. The case underscores ongoing regulatory scrutiny surrounding clinical trial disclosures in the gene therapy sector, where accurate reporting of developmental progress and trial outcomes remains central to investor decision-making.
Prospective class members have until April 14, 2026 to petition the court for lead plaintiff status in the case. Interested parties are advised to review the litigation details and determine their eligibility based on the investment period and security purchases outlined in the complaint.